--- title: "Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT" type: "News" locale: "en" url: "https://longbridge.com/en/news/285960241.md" description: "Alpha Tau Medical Ltd presented interim data from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma on May 11, 2026. The update indicates incremental clinical progress but does not commit to specific regulatory outcomes. The company is also pursuing studies in other cancers, aiming for U.S. regulatory submissions. Analysts rate DRTS stock as a Buy with a $12.00 price target, though concerns about financial performance and funding risks persist. Alpha Tau focuses on localized cancer treatment using its radiotherapy platform targeting hard-to-treat tumors." datetime: "2026-05-11T13:57:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285960241.md) - [en](https://longbridge.com/en/news/285960241.md) - [zh-HK](https://longbridge.com/zh-HK/news/285960241.md) --- # Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest update is out from Alpha Tau Medical Ltd ( (DRTS) ). On May 11, 2026, Alpha Tau Medical presented interim clinical data from its U.S. REGAIN trial of Alpha DaRT in patients with recurrent glioblastoma during a conference call and webcast, and simultaneously posted the accompanying slide deck on its website. The disclosure, furnished to the SEC on Form 6-K rather than filed, underscores that the company is sharing mid-study information on this high-need brain cancer indication while emphasizing that the materials are provided as of that date and may not be updated, signaling incremental but non-decisive clinical progress for investors and other stakeholders. Alpha Tau framed the update within a broader development timeline that includes a multi-center pivotal study in recurrent cutaneous squamous cell carcinoma, feasibility work in pancreatic cancer and early-stage studies in recurrent glioblastoma, all aimed at eventual U.S. regulatory submissions. By formally furnishing the REGAIN interim data and highlighting its anticipated milestones, the company is reinforcing its U.S. oncology pipeline narrative without yet committing to specific regulatory outcomes, leaving the ultimate clinical and commercial impact contingent on future trial results and approvals. The most recent analyst rating on (DRTS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page. **Spark’s Take on DRTS Stock** According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral. The score is held back primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn), which increases funding and dilution risk. Technicals are more constructive on a longer-term basis (above 50/100/200-day averages with neutral momentum), but valuation is limited by negative earnings and no dividend support. To see Spark’s full report on DRTS stock, click here. **More about Alpha Tau Medical Ltd** Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, a radiotherapy platform that uses diffusing alpha-emitters for localized cancer treatment. The company is targeting hard-to-treat solid tumors, including recurrent cutaneous squamous cell carcinoma, pancreatic cancer and recurrent glioblastoma, with a focus on progressing U.S. clinical trials toward potential FDA approvals. **Average Trading Volume:** 332,975 **Technical Sentiment Signal:** Buy **Current Market Cap:** $749M Learn more about DRTS stock on TipRanks’ Stock Analysis page. ### Related Stocks - [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md) - [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md) ## Related News & Research - [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md) - [Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 | DRTS Stock News](https://longbridge.com/en/news/281194699.md) - [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md) - [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md) - [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)